Product Program year 2025 Source: CMS Open Payments

Pedvaxhib

Biological Vaccine

NDC 0006-4897-00

Open in the dashboard

General payments

$46,330

545 payments

Research payments

$10,280

1 payment

Through program year 2025, $46,330 in general payments and $10,280 in research payments were reported against Pedvaxhib (Vaccine).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Amount Payments
2025 General $24,219 114
2024 General $17,183 146
2023 General $766 41
2022 General $2,377 139
2022 Research $10,280 1
2021 General $1,258 71
2020 General $526 34

Breakdown

Who paid General payments · program years 2020–2025
  1. Merck Sharp & Dohme Corporation $46,330 545 payments
Top recipients General payments · program year 2025
  1. Inova Fairfax Hospital Teaching hospital · VA $6,000 25% · 2 payments
  2. University Of Iowa Hosp & Clinics Teaching hospital · IA $3,750 15% · 3 payments
  3. The University Of Texas Medical Br. Teaching hospital · TX $2,500 10% · 1 payment
  4. Childrens Hospital Teaching hospital · DC $2,500 10% · 1 payment
  5. University Of Virginia Medical Cente Teaching hospital · VA $1,800 7% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pediatrics $1,084 56% · 54 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $352 18% · 17 practitioners
  3. Nurse Practitioner, Pediatrics Nurse Practitioner $178 9% · 10 practitioners
  4. Physician Assistant $75 4% · 4 practitioners
  5. Family Medicine $40 2% · 2 practitioners

The top 5 of 13 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Virginia $7,823 32% · 3 recipients
  2. Iowa $3,750 15% · 1 recipient
  3. Texas $2,617 11% · 5 recipients
  4. District of Columbia $2,500 10% · 1 recipient
  5. Florida $1,594 7% · 37 recipients

The top 5 of 21 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

215

Prescriptions dispensed, refills included

Drug cost

$8,969

Paid at the pharmacy, in all

Prescribers

12

With 11 or more claims of it

Medicare Part D drugs matched to PEDVAXHIB, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Pedvaxhib Haemph B Polysac Conj-Menin/Pf Same name 12 215 $8,969

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 12 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Rebecca Tokarski Physician Assistant OH 30 $1,096 None on record
Sara Holstein Hematology-Oncology NE 30 $873 None on record
Steven Kroft Pathology WI 24 $1,253 None on record
Julie Vose Hematology NE 18 $531 None on record
Jennifer Morse Family Practice MI 16 $899 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 12 in the dashboard with a free account
545 general · 1 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record